Pharma Focus Asia

WuXi Biologics Expands Drug Manufacturing Capacity

Introduction:

WuXi Biologics plans to expand manufacturing capacity for drug substance and drug product.

Features:

The state-of-the-art drug substance facility laid with 30,000 square metres is expected to double from 12,000 litres to 24,000 litres. This will greatly increase the manufacturing capacity for drug substances, supporting both clinical and commercial production.

The expansion of the sterile filling and freeze-drying plant is aimed at increasing its annual capacity to approximately ten million doses. The addition of a second variable filling line will allow for more efficient and flexible production processes. 

This expansion is a significant step in enhancing the plant's capabilities and meeting the growing demand for pharmaceutical products.

The investment in these facilities not only adds new capacity but also enhances the existing manufacturing services by strengthening the team's ability to provide timely support in advancing their biologics towards commercialisation. 

Specifications:

Name       WuXi Biologics
Type         Expansion
 

Latest Issue
Get instant
access to our latest e-book
MFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Gibco Adherent Kidney Media PanelCPHI Korea 2024Equinix accelerated medical research...CHEMICAL INDONESIA 2024Thermofisher - Antibody Therapeutic PolishingINALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024
Searching for an end-to-end patient tech solution?